Cancer is a leading cause of death for children and adolescents worldwide. Brain tumors are among the most common childhood cancers and one of the most difficult to treat. However, advances are being made across the field of cancer treatment, including in the identification of neoantigens as the future of personalized cancer vaccines. Neoantigens are targets that can be utilized by immunotherapy, a form of therapy that uses a patient’s own immune system to attack a tumor. Previous work has highlighted that neoantigens are also expected to be key markers for prediction of response to immune checkpoint blockers. These checkpoints help keep immune responses from being too strong and sometimes can keep the immune system from killing cancer cells, and checkpoint blockers are used to prevent this and strengthen immune response against cancers. For an enhanced prediction of neoantigens, researchers plan to integrate a new approach for fusion gene detection into the currently available toolkit for neoantigen detection. Researchers will carry out this research on the comprehensive data provided through the Pediatric Brain Tumor Atlas.
What are the goals of this project?
Neoantigens are targets that can be utilized by immunotherapy, and researchers on this project seek to identify neoantigens in patients with pediatric brain cancers.
What is the impact of this project?
Neoantigens are considered an important piece of the future of personalized therapies, and their identification in this project will pave the way for advancements in the treatment of pediatric brain cancers.
Why is the CBTN request important to this project?
Researchers need extensive data on pediatric brain cancers to complete this work, and the Pediatric Brain Tumor Atlas will provide such data across a wide variety of pediatric brain cancers.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.